Delgocitinib is primarily used in the treatment of chronic skin conditions, particularly atopic dermatitis. It functions as a JAK inhibitor, targeting specific pathways in the immune system that contribute to inflammation and skin irritation. By modulating these pathways, it helps reduce symptoms such as itching, redness, and swelling, providing relief to patients with moderate to severe cases. Its topical application makes it a convenient option for localized treatment, minimizing systemic side effects. Delgocitinib is especially beneficial for individuals who have not responded well to traditional therapies, offering an alternative approach to managing persistent skin inflammation.